Clinical trials: Advanced or Metastatic Solid Tumor
Solid Tumors
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
This study will be conducted in 5 parts (Parts A, B, C, D and E). Monotherapy Treatment: Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A.
- Trial name
- NCT02628574
- Testing
- TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Leap Therapeutics, Inc.
Neoplasms
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel.
- Trial name
- NCT01938846
- Testing
- BI 860585, exemestane, paclitaxel
- Where
- 4 sites in Belgium, Italy
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Metastatic Cancer
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid…
- Conditions
- Solid Tumor, Metastatic Cancer, Unresectable Solid Tumor, Recurrent Solid Tumor
- Trial name
- Tumorad (NCT06184035)
- Testing
- [177Lu]Lu-SN201
- Where
- 2 sites in Australia
- Volunteers
- 90 people
- Sponsor
- Spago Nanomedical AB
Advanced Solid Tumor Malignancies
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.
- Trial name
- NCT07475559
- Testing
- JSKN016HC
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Cancer
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of PAN-NeoVax, an artificial intelligence (AI)-designed pan-cancer…
- Trial name
- NCT07560943
- Testing
- PAN-NeoVax (25 μg), PAN-NeoVax (50 μg), PAN-NeoVax (100 μg)
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Advanced Solid Tumors
Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors
Part A: The purpose of this study is to find the maximum tolerated dose of BMS-777607 in subjects with advanced or metastatic solid tumors Part B: The purpose of this study is to describe the preliminary activity of BMS-77607 in…
- Trial name
- NCT00605618
- Testing
- BMS-777607
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, MET Exon 14 Skipping Mutation
Tepotinib in Solid Tumors Harboring MET Alterations
The aim of this study is to understand efficacy of tepotinib in patients with solid cancers harbouring c-MET amplification or exon 14 mutation who progressed after standard treatment for metastatic disease.
- Conditions
- Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification
- Trial name
- NCT04647838
- Testing
- Tepotinib
- Where
- 22 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Chungbuk National University Hospital
Solid Tumor, Metastatic Cancer
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all…
- Trial name
- NCT03835949
- Testing
- TJ004309, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Solid Tumor
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and…
- Trial name
- NCT07003321
- Testing
- HRS-4508 tablet
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumors, Metastatic Disease
CPCT-05 Biopsy Protocol Patient Selection
Our knowledge on the genetic mutations in cancer is rapidly expanding and we are increasingly testing drugs in mainly metastatic cancer patient populations with rare mutations.
- Trial name
- NCT01904916
- Testing
- Histological biopsy procedure
- Where
- 3 sites in Netherlands
- Volunteers
- 195 people
- Sponsor
- P.O. Witteveen
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Solid Tumor, Advanced Cancer
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
- Trial name
- NCT04419532
- Testing
- DS-1055a
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells.
- Trial name
- NCT00095914
- Testing
- paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Malignant Solid Tumor, Metastatic EphA2 Positive Cancer
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
This was a Phase 1, dose-escalation, non-randomized, open-label, single-center study of DS-8895a in patients with advanced or metastatic Ephrin type-A receptor 2 (EphA2)-positive cancers.
- Trial name
- LUD2014-002 (NCT02252211)
- Testing
- DS-8895a 1 mg/kg, DS-8895a 3 mg/kg, DS-8895a 10 mg/kg
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2…
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
- Trial name
- IL Believe (NCT05081609)
- Testing
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 320 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Advanced Cancer, Metastatic Cancer
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or metastatic solid tumors.
- Conditions
- Advanced Cancer, Metastatic Cancer, Neoplasms, Neoplasm Metastasis
- Trial name
- NCT03510104
- Testing
- MRX-2843
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Meryx, Inc.
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma